There are currently 433 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
Precise Oncology Interventions in Nutrition and Training (OnPoint)
NCT06534918
Recruiting
The purpose of this study is to see if survivors of breast, prostate, or colorectal cancer who receive a personal referral to a targeted nutrition and exercise program will be able to eat a healthier diet and be more physically activity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: University of Miami, Miami, Florida
Conditions: Breast Cancer, Prostate Cancer, Colorectal Cancer
Register for Updates
Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients with Hormone Receptor-Positive HER2-negative Breast Cancer
NCT06361940
Recruiting
This is an exploratory phase II interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for 4-12 weeks (+/- 2 weeks).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Breast Cancer
Register for Updates
Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus
NCT05508906
Recruiting
This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: OP-1250 in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment Group 2: OP-1250 in combination with alpelisib (PIQRAY®, Novartis Pharmaceuticals Corporation). Treatment Group 3: OP-1250 in combination with everolimus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +15 locations
Conditions: Metastatic Breast Cancer, Advanced Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, Breast Cancer
Register for Updates
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
NCT04454528
Recruiting
The primary objective is to determine the feasibility of combining pembrolizumab with a single fraction radiation boost in patients with early/ operable breast cancer. The secondary objectives are to assess clinical response on pre- and post-treatment clinical, imaging, and histology exams, and to assess immune response on pre and post treatment blood and tissue samples by tracking change in Ki67 + CD8 T cells in peripheral blood and in extent of tumor infiltrating lymphocytes. A clinically sign... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania
Conditions: Breast Cancer
Register for Updates
Improving Genetic Counseling for BRCA+ Mothers
NCT04258280
Recruiting
Genetic counseling and testing for hereditary breast cancer may reveal that you, and possibly your blood relatives, are at increased risk for the disease across the lifespan. This includes biological children, both male and female. We do not yet know the best ways to educate mothers who have a risk gene (are BRCA+) about whether, when, and how to share genetic information with their children or manage their thoughts and feelings. The purpose of this study is to help mothers make more informed ch... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/25/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Breast Cancer
Register for Updates
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
NCT05721248
Recruiting
This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: Mayo Clinic Hospital Arizona, Phoenix, Arizona +12 locations
Conditions: Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer
Register for Updates
EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer
NCT06115486
Recruiting
The purpose of this research study is to evaluate the outcomes of two standard of care group exercise regimens to increase muscle mass in women who have been treated with breast cancer.
Gender:
FEMALE
Ages:
Between 20 years and 89 years
Trial Updated:
09/20/2024
Locations: Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Breast Cancer, Breast Carcinoma in Situ, Breast Cancer Female
Register for Updates
Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors
NCT06162663
Recruiting
Investigators propose a double-blind, placebo-controlled trial evaluating the use of the use of Suvorexant in breast cancer survivors on selective estrogen receptor modulators or aromatase inhibitors with sleep disturbance to assess the impact on insomnia symptoms and quality of life. Breast cancer survivors have an increased risk of insomnia for which Suvorexant has the has the potential ability to impact to improve sleep related outcomes and cancer survivorship outcomes. Breast cancer survivor... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/20/2024
Locations: MUSC Department of Family Medicine, Charleston, South Carolina
Conditions: Breast Cancer, Insomnia
Register for Updates
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
NCT04837209
Recruiting
This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer. The names of the study treatment involved in this study are: * Dostarlimab * Niraparib * Radiation Therapy (RT), which is given per standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2024
Locations: Sibley Memorial Hospital, Washington, District of Columbia +3 locations
Conditions: Breast Cancer, Triple Negative Breast Cancer
Register for Updates
Investigating the Use of TaVNS to Treat Insomnia in Individuals with Breast Cancer (taVNS-insomnia-BC)
NCT06006299
Recruiting
In the present study, the investigators aim to investigate feasibility of utilizing noninvasive neuromodulation, specifically taVNS, as a nonpharmacologic approach to address insomnia in patients with stage I-IV breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: UAB Lakeshore Collaborative (WHARF), Birmingham, Alabama +1 locations
Conditions: Breast Cancer, Insomnia
Register for Updates
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
NCT04756765
Recruiting
This purpose of this study is to test if talazoparib is safe and evaluate its response to advanced breast cancer associated with mutation of gene called PALB.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/14/2024
Locations: Stanford University, Stanford, California
Conditions: Breast Cancer, Advanced Breast Cancer
Register for Updates
Improving Care for Rural Patients With Solid Tumors
NCT04916990
Recruiting
This study will assess if the CARES (Cancer Advocacy, Resources, Education and Support) intervention improves time to start of treatment after diagnosis and time to treatment completion for solid tumors (ex: lung, head, neck, thyroid, cervical, breast, bladder, colon, and rectal cancers) in rural patients.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
09/13/2024
Locations: University of Colorado Hospital, Aurora, Colorado +11 locations
Conditions: Lung Cancer, Head and Neck Cancer, Thyroid Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Colon Cancer, Rectum Cancer
Register for Updates